| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1132fb7f604ffacaf15a7d01d25994b1 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 |
| filingDate |
2017-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e6bd62f584e48b4001661a46e27531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65a884353d3de15a4bc41736554a360d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1f9c865238791f4c0b5fd667db300fe |
| publicationDate |
2019-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190091461-A |
| titleOfInvention |
Compositions comprising methylphenidate-prodrug, methods of making and using the same |
| abstract |
The present technology relates to compositions comprising d-threomethylphenidate conjugates and non-conjugate methylphenidates. The present technology also provides d-threomethylphenidate conjugated to nicotinoyl-L-serine, and / or pharmaceutically acceptable salts thereof, and non-conjugated methylphenidate and / or pharmaceutically acceptable salts thereof. It relates to a composition and oral formulation comprising a. The technology further provides d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and / or pharmaceutically acceptable salts thereof, and non-conjugated methylphenidate and / or pharmaceutically acceptable salts thereof. A pharmaceutical kit containing a composition comprising a salt. |
| priorityDate |
2016-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |